A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma-Reference-Cited by-全球学者库

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

Published:2017-05-03 Issue:4 Volume:178 Page:547-560
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Laubach Jacob P.¹^ORCID,Moslehi Javid J.²,Francis Sanjeev A.³,San Miguel Jesús F.⁴,Sonneveld Pieter⁵,Orlowski Robert Z.⁶,Moreau Philippe⁷^ORCID,Rosiñol Laura⁸,Faber Edward A.⁹,Voorhees Peter¹⁰,Mateos Maria-Victoria¹¹,Marquez Loreta¹²,Feng Huaibao¹²,Desai Avinash¹³,van de Velde Helgi¹⁴,Elliott Jennifer¹⁴,Shi Hongliang¹⁴,Dow Edward¹⁵,Jobanputra Nishith¹⁴,Esseltine Dixie-Lee¹⁴,Niculescu Liviu¹⁴,Anderson Kenneth C.¹,Lonial Sagar¹⁶,Richardson Paul G.¹

Affiliation:

1. Dana-Farber Cancer Institute; Boston MA USA

2. Cardiovascular Division; Vanderbilt-Ingram Cancer Center; Cardio-Oncology Program; Vanderbilt University School of Medicine; Nashville TN USA

3. Formerly Cardio-Oncology Program; Massachusetts General Hospital; Boston MA USA

4. Clinica Universidad de Navarra; IDISNA; Centro Investigación Medica Aplicada (CIMA); Pamplona Spain

5. Department of Haematology; Erasmus Medical Centre; Rotterdam The Netherlands

6. Department of Lymphoma/Myeloma; The University of Texas M. D. Anderson Cancer Center; Houston TX USA

7. University Hospital Nantes; Nantes France

8. Hospital Clínic de Barcelona; IDIBAPS; Barcelona Spain

9. Oncology/Hematology Care; Cincinnati OH USA

10. Department of Hematologic Oncology and Blood Disorders; Levine Cancer Institute; Charlotte NC USA

11. Instituto de Investigación Biomédica de Salamanca; Instituto de Biología Molecular y Celular del Cáncer; Hospital Universitario Salamanca; Universidad de Salamanca-Consejo Superior de Investigaciones Cientificas; Salamanca Spain

12. Janssen Research & Development LLC; Raritan NJ USA

13. Janssen Global Services LLC; Raritan NJ USA

14. Millennium Pharmaceuticals Inc.; Cambridge MA USA

15. Foundation Medicine, Inc.; Cambridge MA USA

16. Winship Cancer Institute of Emory University; Atlanta GA USA

Funder

Millennium Pharmaceuticals Inc.

Janssen Global Services LLC

Publisher

Wiley

Subject

Hematology